2-[6-[2-[4-Methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-5-yl]propan-2-ylsulfanyl]-1-benzofuran-3-yl]acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[6-[2-[4-Methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-5-yl]propan-2-ylsulfanyl]-1-benzofuran-3-yl]acetic acid
• 化学式: C₂₄H₂₀F₃NO₄S
• 分子量: 475.5
• InChiKey: NSBICDHFGBCYQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Fused heterocyclic derivates as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060217374A1

  公开（公告）日：2006-09-28

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过利用结构式（I）的化合物来调节过氧化物酶体增殖物激活受体进行治疗的方法。I中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为在治疗和预防综合征X、H型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉粥样硬化和其他与综合征X和心血管疾病相关的疾病方面具有疗效。
• FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1581521A1

  公开（公告）日：2005-10-05
• US7528160B2
  申请人：——

  公开号：US7528160B2

  公开（公告）日：2009-05-05
• [EN] FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS<br/>[FR] DERIVES HETEROCYCLIQUES FUSIONNES UTILISES EN TANT QUE MODULATEURS PPAR
  申请人：LILLY CO ELI

  公开号：WO2004063190A1

  公开（公告）日：2004-07-29

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.